Project

Lumox

Many people with head and neck cancer face harsh treatments like surgery, radiation, or chemotherapy: treatments that often damage speech, swallowing, or appearance. And even then, the cancer sometimes comes back. That can be done better.  There is a critical need for therapies that can selectively eliminate tumor cells while preserving healthy tissue.

Lumox’s innovative approach, Rapid PhotoTherapy (RPT), offers a groundbreaking solution by combining highly selective nanobodies with light-activatable drugs. Patients will get an injection with their medicine, which will automatically “target” the tumor. Once this combination finds the tumor, doctors shine harmless light on the tumor, activating the medicine and destroying the tumor. What makes their treatment special is that it’s fast, targeted, and doesn’t harm healthy tissue. This could help patients keep their voice or ability to eat, and recover more quickly.

One of the other innovative aspects of this therapy includes its fast pharmacokinetics and short photosensitivity window, making it ideal for use as a neoadjuvant therapy. Beyond its application in head and neck cancers, RPT shows promise for other solid tumors accessible by light.
With support from the Biotech Booster program, Lumox will improve the production process of their medicine to prepare for future use in humans. They will also perform in vitro toxicity and pharmacology studies, and want to show in mice that the therapy truly works better than current alternatives. When successful, their therapy could improve the quality of life and outcomes for thousands of cancer patients every year.

Project team

Dr. Sebas Pronk & Dr. Irati Beltrán Hernández

Project Number

BIOB25013

Year granted

2025

Status

Ongoing

Applicant

Utrecht University

Funding

€ 200.000

Sector/Industry

Health & Pharma

SDG's

Good health and well-being (SDG 3)
Decent work and economic growth (SDG 8)
Industry, innovation and infrastructure (SDG 9)

Thematic Cluster

TC3: ATMPs, Biopharmaceuticals & Associated Enabling Technologies

Level

Level 1
Molecuul

2025

Year granted

Utrecht University

Applicant

€ 200.000

Project funded
Project story

Plant Beams: breaking through the plant barrier

The question that started Plant Beams For over ten years, David Fernández Rivas has worked on a technology that uses

Plant Beams: breaking through the plant barrier
Project story

SideroFORCE: Tricking bacteria to heal infection

We interviewed Wim Velema, projectleader of Biotech Booster project SideroFORCE, which joined our program in 2025. At sixteen, Wim liked

SideroFORCE: Tricking bacteria to heal infection
IBB

Behind the Bootcamp: Meet the IBB26 Coaches

Building an industrial biotech venture takes more than a great scientific idea. It requires the ability to challenge assumptions, make

Behind the Bootcamp: Meet the IBB26 Coaches
Project story

From Luggage Tags to Better Food

From fragmented DNA to better food on our plates. We interviewed Biotech Booster project Haplotagging to learn more about their

From Luggage Tags to Better Food
Impact developer portrait

The Innovation Journey at the Universities of Applied Sciences

Impact Developers help researchers turn their ideas into innovations that impact society. They connect researchers with companies and other partners

The Innovation Journey at the Universities of Applied Sciences
Alumni Column

Alumni column: Patrick Dekker from iProtics

On both sides of the table. Some people know Biotech Booster from the outside. Others experience it from the inside,

Alumni column: Patrick Dekker from iProtics
Citaat

Biotech Booster helps us through funding and by providing us with a network to validate where we can make the best impact with our new analysis device.

Biotechnology netherlands

Carlos de Lannoy

Constellate

Citaat

What we look forward to most is leveraging the extraordinary network of Biotech Booster that we need to get foot in the market, get know-how, and understanding the competitive field which is necessary for setting up successful operations.

Biotechnology netherlands

Pim Schaasberg & Martin Pabst

ProteoT

Moleculen

Newsletter

Receive monthly updates about our community!

Subscribe to our newsletter